Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

Autor: Mooney, T, Conteh, L, Bangura, MS, Bangura, MA, Jalloh, H, Kamara, I, Kamara, M, Koroma, S, Sesay, M, Sesay, MT, Deen, AT, Kamara, A, Kamara, EL, Kamara, SLM, Koroma, AH, Mansaray, IS, Massaquoi, MJ, Nabie, A, Kowuor, D, Njie, Y, Odeny, L, Sheku, M, Jalloh, AB, Sow, A, Swaray, E, Mansaray, F, Sessie, T, Sunders, J-HC, Turay, SI-S, Weekes, J, Pessima, M, Wurie, A, Conteh, M, Jalloh, MI, Kamara, PBD, Kanneh, DP, Kanneh, M, Komeh, I, Koroma, M, Kuyateh, M, Mansaray, FF, Leigh, B, Watson-Jones, D, Samai, M, Deen, GF, Sesay, T, Piot, P, Greenwood, B, Lees, S, Larson, H, Afolabi, M, Ishola, D, Baiden, F, Faye, F, Tindanbil, D, Kamara, MM, Swaray, IB, Bangura, A, Kamara, AB, Morovia, FE, Kallon, JA, Murray, M, Sesay, F, Suma, F, Sesay, IG, Choi, EM, Manno, D, Foster, J, Rwezaula, R, Akhigbe, I, Adetola, H, Kamara, B, Lowe, B, Lawal, B, Kohn, B, Tuda, GO, Koroma, F, Bangura, G, Kroma, MT, Fofanah, L, Pessima, A, Rogers, M, Sheriff, O, Fangawa, J, Foday, S, Jabbie, I, Mansaray, HA, Sesay, K, Jakema, HB, Sheku, MF, Jalloh, KFN, Kabba, M, Kanjie, F, Kanu, AP, Kassa-Koroma, G, Jusu, M, Koroma, B, Borboh, P, Kallon, A, van Roey, K, Conteh, P, Samura, M, Gandie, V, Marrah, M, Kalokoh, J, Bangura, MI, Connor, N, Saidu, S, Turay, AS, Lahai, A, Johnson, CL, Kogba, DB, Vincent, W, Bangura, M, Tengbeh, A, Bangura, K, Kabia, R, Nyakoi, AM, Lee, S, Nyaberi, D, Ndingi, S, Nyallay, L, Bangura, AR, Idriss, B, Sillah, M, Mackay, W, Murray, T, Edem-Hotah, J, Fatorma, T, Bangura, S, Bonnie, E, Sannoh, M, Malcolm, S, Brown, J, Snowden, E, Howard, K, Ojugo, A, Massin-Shepherd, C, BEAVOGUI, AH, KEITA, CM, CAMARA, OK, GUILAVOGUI, JPY, BAH, H, SAMOURA, MA, MUAMBA, D, SEMAKUBA, B, CAMARA, AK, KABA, AS, BERERD-CAMARA, M, YARADOUNO, M, DECHENAUD, M, CAMARA, MT, TAMBALOU, J, HABA, M, DIALLO, SD, THEA, A, DOUMBOUYA, N, FOFANA, ML, BEAVOGUI, M, CAMARA, AA, BEAVOGUI, JT, DIOUF, W, AUGIER, A, BARTE DE SAINTE FARE, E, SIVAHERA MUYISA, B, SANI, S, VATRINET, R, HAMZE, B, LACARRA, B, D’ORTENZIO, E, ALE, B, BETARD, C, RICHERT, L, OULAI, D, KANTE, M, SOUTTHIPHONG, A-A, SCHWIMMER, C, THIÉBAUT, R, OTTAVI, A, COUFFIN-CADIERGUES, S, ESPEROU, H, Chai, SP, Buth, W, Offergeld, K, Menten, A, Hammoud, N, De Ridder, S, Sellecchia, R, in ’t Veld, R, Fogap, N, Anumendem, D, Stapleton, H, Reijns, T, Haydon, J, Roza, L, Sawyer, B, Hoda, S, Yee, J, De Cnodder, T, Hubin, E, Telen, L, Desai, J, Bennet, M, Pawlowski, M, van Gils, N, Boeykens, N, Kwasniak, A, Ligthart, M, Van Roey, G, Fernandez, E, Gaddah, A, van Dijck, W, Jingshuang, S, Randrasana, S, Artis, C, Akinbinu, A, Poretti, A, Van Ballaert, S, Harris, M, Van Looveren, M, Brandt, P, Robinson, C, Bockstal, V, McLean, C, Versteege, I, Ferrault, C, Kaminski, A, Vergauwen, H, Kerama, CI, Forcheh, CA, DiMondi, CV, Stewart, L, Meurer, J, Beounitis, A, Peeters, J, Su, C, Keshinro, B, Delport, C, Sharkie, E, Zhang, J, Du, C, Hu, K, Strydom, A, Bezem-Aviv, I, Wachnicka, A, Kumar, P, Cheng, S, Kang, K, Choi, Edward Man-Lik ^*, Lacarra, Boris, Afolabi, Muhammed O, Ale, Boni Maxime, Baiden, Frank, Bétard, Christine, Foster, Julie, Hamzé, Benjamin, Schwimmer, Christine, Manno, Daniela, D’Ortenzio, Eric, Ishola, David, Keita, Cheick Mohamed, Keshinro, Babajide, Njie, Yusupha, van Dijck, Wim, Gaddah, Auguste, Anumendem, Dickson, Lowe, Brett, Vatrinet, Renaud, Lawal, Bolarinde Joseph, Otieno, Godfrey T, Samai, Mohamed, Deen, Gibrilla Fadlu, Swaray, Ibrahim Bob, Kamara, Abu Bakarr, Kamara, Michael Morlai, Diagne, Mame Aminata, Kowuor, Dickens, McLean, Chelsea, Leigh, Bailah, Beavogui, Abdoul Habib, Leyssen, Maarten, Luhn, Kerstin, Robinson, Cynthia, Douoguih, Macaya, Greenwood, Brian, Thiébaut, Rodolphe, Watson-Jones, Deborah

Publikováno v: In The Lancet Global Health November 2023 11(11):e1743-e1752

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Root contrast enhancement for measurement with optical scanner-based image analysis.

Autor: Costa, C, Dwyer, L M, Hamel, C, Muamba, D F, Wang, X L, Nantais, L, Smith, D L

Publikováno v: Canadian Journal of Botany; Jan2001, Vol. 79 Issue 1, p23-29, 7p

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.

Autor: Valayer S; Infection, Antimicrobials, Modelling, Evolution (IAME), Université Sorbonne Paris Nord, Université Sorbonne Paris Cité, and Institut national de la santé et de la recherche médicale (Inserm), Paris, France.; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France., Alexandre M; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France., Prague M; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France., Beavogui AH; Centre National de Formation et de Recherche en Santé Rurale (CNFRSR) de Mafèrinyah, Ministère de la Santé et de l'Hygiène Publique, Mafèrinyah, Guinea., Doumbia S; University Clinical Research Center, University of Sciences, Technique and Technology of Bamako, Bamako, Mali., Kieh M; Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia., Greenwood B; London School of Hygiene & Tropical Medicine (LSHTM), London, UK., Leigh B; College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone., Poupelin M; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France., Schwimmer C; European Clinical Trials Platform & Development (EUCLID), Université de Bordeaux, Centre Hospitalier Universitaire Bordeaux, and Inserm, ISPED, Bordeaux, France., Sow SO; Centre pour le Développement des Vaccins, Ministère de la Santé et du Développement Social du Mali, Bamako, Mali., Berry IM; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, MD, USA., Kuhn JH; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, MD, USA., Fusco D; French Agency for Research on AIDS and Viral Hepatitis (ANRS), Emerging Infectious Diseases, PariSanté Campus, Paris, France.; Department of Infectious Diseases Epidemiology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany., Cauwelaert ND; Inserm, Paris Cedex 13, France., Watson-Jones D; London School of Hygiene & Tropical Medicine (LSHTM), London, UK., Thiébaut R; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.; European Clinical Trials Platform & Development (EUCLID), Université de Bordeaux, Centre Hospitalier Universitaire Bordeaux, and Inserm, ISPED, Bordeaux, France.; Pôle de Santé Publique, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France., Lévy Y; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.; Inserm, Paris Cedex 13, France.; Service d'Immunologie Clinique et Maladies Infectieuses, Hôpital Henri-Mondor, Créteil, France., Yazdanpanah Y; Infection, Antimicrobials, Modelling, Evolution (IAME), Université Sorbonne Paris Nord, Université Sorbonne Paris Cité, and Institut national de la santé et de la recherche médicale (Inserm), Paris, France.; Inserm, Paris Cedex 13, France.; Service de Maladies Infectieuses et Tropicales, Hôpital Bichat, Paris, France., Richert L; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.; European Clinical Trials Platform & Development (EUCLID), Université de Bordeaux, Centre Hospitalier Universitaire Bordeaux, and Inserm, ISPED, Bordeaux, France.; Pôle de Santé Publique, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France., Lhomme E; Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.; Vaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, France.; European Clinical Trials Platform & Development (EUCLID), Université de Bordeaux, Centre Hospitalier Universitaire Bordeaux, and Inserm, ISPED, Bordeaux, France.; Pôle de Santé Publique, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France., Aboulhab J; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Aguirre-MacKenzie M BS; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Akoo P MB, ChB; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Akpa E MSN, MPH, RN; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Akpata R; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Albert S BA, MPH; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Ale BM MD, MSc, MPH; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Alimamy-Bangura S MB, ChB; (AF0111) College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone, Andong P MSt; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Andrews BC; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Anoma S; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Atri N MPH, CPH; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Augier A MCom; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Awuondo K MSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Ayouba A; (AF0130) Recherche Translationnelle Appliquée au VIH et aux Maladies Infectieuses, Institut de Recherche pour le Développement, University of Montpellier, INSERM, 34090, Montpellier, France, Badio M MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Bagayoko A; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Balde A MPH; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Balssa J PharmD; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF018) ANRS Emerging Infectious Diseases, Paris, France, Bangura LM BSc; (AF0111) College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone, Barrington K MPA; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Barte de Saint Fare E BA; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Baseler B MS; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Bauder A BA, PMP; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Bauduin C MSc; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Bawo L MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Beavogui AH MD, PhD; (AF019) Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, Guinea, Belson M BS; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Ben-Farhat S MEng; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Bererd M BS; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Bernaud N MSc; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Beyslow T PharmD; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Biai N MSc; (AF0130) Recherche Translationnelle Appliquée au VIH et aux Maladies Infectieuses, Institut de Recherche pour le Développement, University of Montpellier, INSERM, 34090, Montpellier, France, Billioux J; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Billouin-Frazier S MSc; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Binachon B MD, MPH; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Blie J MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Bockstal V; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Boison P MS; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Bolay F; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Boly A MM; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Bonawitz RE MD, MS; (AF0122) Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street Baltimore, MD, 21201-1509, USA, Borg AG MCM; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Bosompem S PharmD, MSc; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Bozman C MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Brady T MPH; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Browne S RN, BSN; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Bullis R; (AF0122) Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street Baltimore, MD, 21201-1509, USA, Cagniard B; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Cahill K RN, MSc, CCRC, RAC; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Cai Y; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Camara AA MSc; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Camara AK; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Camara AM; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Campagne A; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Campion C MSc; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Cantan A BSc; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France; (AF0129) Univ. Bordeaux, INSERM, MART, UMS 54, F-33000, Bordeaux, France, Cash J BS; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Chai SP BBio-MedSc; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Chambelin F MHist; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Chea M BSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Chêne G MD, PhD; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Choi E; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Chouinard M MSW; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Chung F; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Chung L PharmD; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Ciancia S MJ; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Cisse PN; (AF0114) Département de Sociologie, FLSH, Université Cheikh Anta DIOP, Dakar, Sénégal, Cline-Cole E MA; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Colin C MSc; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Coller BA; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Conde DS; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Cone K, Cone K MSW, LCSW-C, C-SWHC; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Connor L MS; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Connor N MSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Cooper JB MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Couffin-Cardiergues S; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Coulibaly F BS; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Coulibaly M PharmD, MSc; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Crew P PharmD, MPH, BCPS; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Dabakuyo-Yonli S PharmD, PhD; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Dabitao D PharmD, PhD; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Damerval T; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Davis B MPH; (AF015) School of Public Health, University of Minnesota, Minneapolis, MN, USA, Deen GF MD, MSc; (AF0111) College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone, Dekeyster E; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Delfraissy JF MD, PhD; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Delmas C MSc; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Diakite M PharmD, DPhil; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Diallo A MD, MPH; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF018) ANRS Emerging Infectious Diseases, Paris, France, Diallo FA; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Diallo MS MD, MPH; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Diarra A MSc; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Diarra S MSc, PhD; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Diawara O BS; (AF0119) Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali, Dighero-Kemp B BSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Diop S MSc, PhD; (AF0121) Liberia Institute for Biomedical Research Ethics Committee/National, Monrovia, Liberia, Diouf W; (AF0114) Département de Sociologie, FLSH, Université Cheikh Anta DIOP, Dakar, Sénégal, Dixit S; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Djenabou B MSc; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Doepel L BA; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, D’Ortenzio E MD, MPH; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF018) ANRS Emerging Infectious Diseases, Paris, France; (AF017) AP-HP, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, Paris, F-75018, France, Doumbia S MD, PhD; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Doumbia MM; (AF0119) Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali, Douoguih M MD, MPH; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Dozier N MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Cauwelaert ND; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF018) ANRS Emerging Infectious Diseases, Paris, France, DuChêne A BS; (AF015) School of Public Health, University of Minnesota, Minneapolis, MN, USA, Duvenhage M NDIPIT; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Eckes R RN; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Elliott E MSc; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Enria L; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Espérou H; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Etienne C MSc; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Eyler A HSD; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Fakoli L MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Fallah M; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Fauvel MA MSc; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Faye S; (AF0114) Département de Sociologie, FLSH, Université Cheikh Anta DIOP, Dakar, Sénégal, Fayiah J MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Fleck S; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Fofana V BComp; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Tchos KF MD, MPH; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Franklin K MPhil, MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Fusco D; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Gaddah A; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Gaignet M MSc; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Gallagher K; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Gardner J BS; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Gichini H MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Gozalbes JG; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Grandits G MS; (AF015) School of Public Health, University of Minnesota, Minneapolis, MN, USA, Gray M BPharm; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Greenwood B; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Grobler N; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Gross R MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Grue L RN, BS, BSN; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Grund B; (AF0127) School of Statistics, University of Minnesota, Minneapolis, MN, USA, Guindo O MSc, PharmD; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Gupta S DrPH, MPH; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Haidara F; (AF0119) Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali, Hamz B PharmD; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Hancox E MSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Hébert JC MSL; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Hendriks J; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Hensley P MPh; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Hensley LE PhD, MSPH; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Herpin B MSN; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Higgs E MD, DTMH, MIA; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Hilton T BPharm, MSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Hneino M; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Höeltermann TA BSc, MPH; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Holley HP; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Hoover M; (AF0116) Advanced BioMedical Laboratories, L.L.C., 1605 Industrial Hwy, Cinnaminson, NJ, USA, Howard N; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Hughes M BA, MBA, CPM, PMP; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Ilo D MD, MPH; (AF0120) University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali, Irvine S BS; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Ishola D MD, PhD; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Jato Y MPH; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Joe M MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Johnson M MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Kaba AS; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Kagan J; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Kallon K MSc; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Kamara M MBChB, MSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Kante M BS; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Katoudi J MD, MPH; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Keita CM; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Keita S; (AF0115) Agence Nationale de Sécurité Sanitaire, Conakry, Guinea, Keita S; (AF0122) Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street Baltimore, MD, 21201-1509, USA, Kennedy SB MD, MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Keshinro B MBBS, FWACP; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Kiawu H MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Kieh M MD, MSMHC; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Killinger B BA; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Kinda M MD, MBA; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Kirchoff M PharmD, MSc, MBA; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Kocher G MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Kodio M PharmD; (AF0119) Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali, Kohn B BSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Koivogui L PharmD, PhD; (AF0123) INSP (Institut Nationale de Santé Publique), Conakry, Guinea, Kojan R; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Koli CF é, PharmD; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Koli JS é, MD; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Kollie D BSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Kopka S MS; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Koroma B BPharm; (AF0111) College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone, Kowuor D BSc, MSc, PhD; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Kpayieli-Freeman C MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Kwast L MSc; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Lacabaratz C; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF0118) Vaccine Research Institute, Univ. Paris Est Créteil, Henri Mondor Hospital, Créteil, France, Lacarra B; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Lambert L BS; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Lambeth C BS; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Lancrey-javal S PharmD; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF018) ANRS Emerging Infectious Diseases, Paris, France, Lane HC; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, Langba S BSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Lawal B MSc; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Lee AW; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Lee S; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Lees S; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Lefevre A; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Leigh B MD, MSc; (AF0111) College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone, Lemarcis F; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Lévy Y MD, PhD; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France; (AF0118) Vaccine Research Institute, Univ. Paris Est Créteil, Henri Mondor Hospital, Créteil, France, Levy-Marchal C; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Leyssen M MD, PhD; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Lhomme E MD, PhD; (AF0126) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform and U1219 BPH Inria Sistm, F-33000, Bordeaux, France, Liang J MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Linga M MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Liu K; (AF0112) Merck Sharp & Dohme Corp, Inc., Kenilworth, NJ, USA, Lowe B MPhil; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Lysander J MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Mahamadou I PharmD; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Maljkovic-Berry I; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Mambiah M ASc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Manno D MD, PhD; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Marchand J MS; (AF012) National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Marron L MSc; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, Massaquoi MB MD, MSc; (AF0110) Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, Masson L MIBL; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Matard C BS; (AF014) Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, F-33000, Bordeaux, France, Mazur S BS; (AF0128) Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Fort Detrick, Frederick, MD, USA, McCullough J BS; (AF0116) Advanced BioMedical Laboratories, L.L.C., 1605 Industrial Hwy, Cinnaminson, NJ, USA, McFadyen K MPH; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, McLean C; (AF0113) Janssen Vaccines and Prevention BV Leiden, The Netherlands, Mercier N PharmD; (AF011) French Institute for Health and Medical Research (Inserm), 75013, Paris, France, Michavila P BBus; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Miller T RN, BSN; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Millimouno NP; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Miranda A MS; (AF0117) Leidos Biomedical Research, Inc., Frederick, MD, 21704, USA, Mohamed S BJ; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Mooney T BA; (AF013) London School of Hygiene & Tropical Medicine, London, UK, Muamba D; (AF016) The Alliance for International Medical Action, Alima, B.P.15530, Dakar, Sénégal, Mulbah J BPharm; (AF0111) College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone

Publikováno v: Emerging microbes & infections [Emerg Microbes Infect] 2025 Dec; Vol. 14 (1), pp. 2432353. Date of Electronic Publication: 2024 Dec 09.